| Project/Area Number |
25293303
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Fujii Yoshitaka 名古屋市立大学, 医学(系)研究科(研究院), 名誉教授 (40156831)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SASAKI HIDEFUMI 名古屋市立大学, 大学院医学研究科, 研究員 (00336695)
YANO MOTOKI 名古屋市立大学, 大学院医学研究科, 准教授 (40315883)
OKUDA KATSUHIRO 名古屋市立大学, 大学院医学研究科, 助教 (50529170)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2015: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
|---|
| Keywords | RET / EGFR / BRAF / FISH / CASR-PCR / 肺癌 / 増幅 / 転座 / NTRK / 分子標的 / チロシンキナーゼ / 腺癌 / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
Molecular targeted therapies such as gefitinib/erlotinib/afatinib/osimertinib that target EGFR mutations and crizotinib/alectinib that target ALK fusion have demonstrated superior single agent activity in mutant selected patients as compared standard chemotherapy regimens in lung adenocarcinomas. Recently, a series of new gene fusions have been described in patients with lung adenocarcinomas using next generation. We have discovered RET translocation in lung adenocarcinomas. In our cohort, three RET fusion mutants were found. We have developed FISH probes to detect RET translocations. In 2013, we have discovered NTRK1 translocation. We performed cell based assay for the translocations. In 2014, FGFR3 translocations were found. In addition, BRAF V600E is a driver mutation that can be effectively targeted with selective BRAF inhibitors. We investigated BRAF V600E mutations by CAST-PCR and immunohistochemical methods, and confirmed gene amplification by FISH in 2015.
|
